DataMEDS aims to delive a ve tically alig ed healthca e ecosystem to patie ts that expa ds Ei stei Rx™‘s tech ological capabilities i to medical, labo ato y a d wea ables fields th ough a p op ieta y blockchai , leve agi g u ique d ug-adju ct p oducts to tailo patie t-specific solutio s th ough the Health Lives He e app, i itially ta geti g GLP-1-associated muscle loss a d Lo g COVID patie t bases. The Compa y i te ds to leve age Health Lives He e’s u ique patie t-e gageme t i f ast uctu e to co solidate elect o ic health data i to ou p op ieta y health-ce te ed blockchai i f ast uctu e to e able patie ts to pa ticipate i data t a sactio eve ue, educe data f ictio fo p ovide s, a d allow fo tailo ed cli ical t ial offe i gs of both p esc iptio d ugs a d/o p op ieta y ut aceutical p oducts fo patie ts seeki g to each specific health goals.
“T adi g u de the ew symbol ‘MEDS’ is expected to help captu e the atte tio a d focus of the Health IT-focused i vestme t commu ity by immediately alig i g the Compa y’s missio of co ti ually acqui i g a d a alyzi g data with the desi ed outcome of maki g the best t eatme t decisio s a ou d whe to i itiate p esc iptio d ug the apy, whe to adjust dosi g a d/o whe to disco ti ue t eatme t i the mi ds of i vesto s,” said Ge ald Commissio g, I te im Co-CEO of DataMEDS. “Fo patie ts a d healthy use s, DataMEDS i te ds to go fa beyo d existi g health IT platfo ms by p ovidi g ou u ique adju ct atu al p oducts to help imp ove health outcomes of patie ts o p esc iptio GLP-1 t eatme t a d patie ts with Lo g COVID. By captu i g biomet ic data with ou Health Lives He e app, we i te d to go beyo d o e-way i fo matio flow to empowe patie ts to mo e dy amically ma age thei health by atio alizi g wea ables data’s effect o healthca e decisio -maki g.”
Acco di g to SNS I side , the U.S. blockchai i healthca e ma ket was valued at $7.13 billio i 2023 a d is p ojected to each $595.31 billio by 2032, at a compou ded a ual g owth ate (CAGR) of 63.5% (see Datavault AI’s Novembe 25, 2025 Pha macyChai ™ lice se a ou ceme t). Acco di g to Ma ket Resea ch Futu e, the global d o e-e abled medical supplies pickup a d delive y ma ket was valued at $430 millio i 2023 a d is p ojected to each $2.49 billio by 2032, at a CAGR of 21.20%. Acco di g to G a d View Resea ch, the GLP-1 ecepto ago ist ma ket is expected to g ow f om $66 billio i 2025 to $185 billio i 2033, at a CAGR of 12.4%, with skeletal muscle loss docume ted as a key side effect of GLP-1 the apies a d a p ima y ta get i dicatio fo Tollo Health’s p op ieta y suppleme t po tfolio. Acco di g to ma ket esea ch fi m Nova1 Adviso , the U.S. telemedici e ma ket size was $41.54 billio i 2025 a d is p ojected to g ow to $188.05 billio by 2035, ep ese ti g a expected CAGR of 16.3%.
As of the date of this p ess elease, DataMEDS has 2,847,198 commo sha es outsta di g. Ce tai stockholde s holdi g app oximately 1,533,930 commo sha es, ep ese ti g a majo ity of the outsta di g commo sha es, have e te ed i to lock-up ag eeme ts that p eclude the sale of thei sha es i to the ma ket fo at least i ety (90) days f om today’s date. The e a e cu e tly 919,465 DataMEDS commo sha es deposited i Deposito y T ust & Clea i g Co po atio (DTCC) available fo t adi g. The e a e o debt o p efe ed equity secu ities of the Compa y that a e eligible to co ve t i to f ee t adi g commo sha es at the cu e t time. The e is a total of 80,826 cash wa a ts outsta di g, each with a fixed exe cise p ice of $35.00 pe sha e, that a e cu e tly eligible to be exe cised i to f ee t adi g commo sha es. I vesto s should efe to the Compa y’s fili gs with the Secu ities a d Excha ge Commissio fo additio al i fo matio ega di g the Compa y’s capitalizatio a d outsta di g secu ities.
DataMeds AI, I c. (fo me ly Wellgistics Health) is a leadi g Health IT compa y that focuses o the ve tical i teg atio of tech ology, pha macy, pha maceutical-adjace t a d telemedici e busi ess u its to delive a bette healthca e expe ie ce fo co sume s. Headqua te ed i Tampa, Fla., DataMeds AI i co po ates the a tificial i tellige ce platfo m Ei stei Rx™ a d blockchai -e abled sma t co tacts platfo m Pha macyChai ™ i to the Health Lives He e Mobile applicatio a d Tollo Health.
This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995. Fo wa d-looki g stateme ts i clude, without limitatio , stateme ts ega di g the p oposed co po ate ame cha ge to DataMeds AI, I c.; the p oposed eb a di g of the Compa y’s Pha macy a d Pha macy Se vices divisio as Co exa Health; the Compa y’s p oposed t a sactio with DataVault AI I c., Scilex Holdi g Compa y, EOS Holdi gs a d HealthB idge Adviso s; the a ticipated timi g, st uctu e, te ms a d completio of such t a sactio ; the satisfactio o waive of closi g co ditio s; the eceipt of stockholde app oval a d a y othe equi ed app ovals; the Compa y’s a ticipated busi ess st ategy, ope ati g pla s a d g owth oppo tu ities; the i teg atio of telemedici e, pha macy, labo ato y, wea able-device, a tificial i tellige ce, blockchai a d data-ma ageme t tech ologies; the p oposed developme t, comme cializatio a d expa sio of Ei stei Rx AI, Pha macyChai , Health Lives He e a d elated platfo ms; the Compa y’s ability to empowe patie ts to access, ma age, co t ol o mo etize health data; the a ticipated be efits of the Compa y’s tech ology platfo ms, st ategic elatio ships a d busi ess combi atio s; the Compa y’s capitalizatio , outsta di g secu ities, lock-up a a geme ts, public float a d egist atio stateme ts; the Compa y’s ability to mai tai complia ce with Nasdaq listi g sta da ds; a d the Compa y’s liquidity, capital esou ces a d ability to fu d ope atio s.
Fo wa d-looki g stateme ts a e based o cu e t expectatio s, estimates, p ojectio s a d assumptio s a d a e subject to isks a d u ce tai ties that could cause actual esults to diffe mate ially f om those exp essed o implied by such stateme ts. These isks a d u ce tai ties i clude, amo g othe s, the isk that the p oposed ame cha ge may ot be app oved by stockholde s o othe wise completed; the isk that the p oposed t a sactio may ot be completed o the a ticipated te ms o timeli e, o at all; the isk that closi g co ditio s may ot be satisfied o waived; isks elated to i teg ati g multiple busi esses, tech ologies a d platfo ms; isks elated to the developme t, comme cializatio , adoptio , scalability a d egulato y t eatme t of a tificial i tellige ce, blockchai -e abled data ma ageme t, telemedici e, pha macy, labo ato y, wea able-device a d digital health tech ologies; isks elated to healthca e p ivacy, cybe secu ity, data ow e ship, data mo etizatio a d complia ce with applicable healthca e, pha macy, co sume p otectio , data p otectio a d secu ities laws; isks elated to the Compa y’s liquidity, capital esou ces, i debted ess, dilutio , outsta di g secu ities, egist atio stateme ts a d ability to aise additio al capital; isks elated to mai tai i g complia ce with Nasdaq listi g sta da ds; ma ket, egulato y, competitive a d ope atio al isks affecti g the healthca e, pha macy, pha maceutical dist ibutio , a tificial i tellige ce, tech ology a d digital asset secto s; a d othe isks desc ibed i the Compa y’s fili gs with the Secu ities a d Excha ge Commissio .
Fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease. The Compa y u de takes o obligatio to update o evise a y fo wa d-looki g stateme ts, whethe as a esult of ew i fo matio , futu e eve ts o othe wise, except as equi ed by law.
James Lambe t, Vice P eside t Rube stei Public Relatio sPho e: 212.805.3024Email:
I vesto Relatio s:
###
